DLPIC
BPMC

Davide Leone & Partners Investment Company’s Blueprint Medicines BPMC Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,837
Closed -$2.32M – 68
2021
Q1 		$2.32M Buy
23,837
+8,845
+59% +$883K 0.29% 39
2020
Q4 		$1.68M Buy
+14,992
New +$1.58M 0.18% 55

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Davide Leone & Partners Investment Company's BPMC Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 23,837 shares — an estimated $2.32M sold.

Davide Leone & Partners Investment Company first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $2.32M in Q1 2021. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 23,837 Blueprint Medicines shares in Q2 2021, an estimated $2.32M.
  • Davide Leone & Partners Investment Company first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Blueprint Medicines position peaked at $2.32M in Q1 2021.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.